Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Journal articles and book chapters

04-28-2018 | Heart failure | Review | Article

SGLT2 inhibition and heart failure: Current concepts

Custodio JS et al. Heart Fail Rev 2018; 23: 409–418. doi: 10.1007/s10741-018-9703-2

04-18-2018 | Linagliptin | Review | Article

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes: Focus on linagliptin

Aroor AR, Manrique-Acevedo C, DeMarco VG. Cardiovasc Diabetol 2018; 17: 59. doi: 10.1186/s12933-018-0704-1

04-10-2018 | Teneligliptin | Article

Safety and efficacy of teneligliptin in patients with type 2 diabetes mellitus and impaired renal function: Interim report from post-marketing surveillance

Haneda M et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0416-2

03-23-2018 | Oral combination medications | Article

SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Li D et al. Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13294

02-12-2018 | Teneligliptin | Article

Efficacy and safety of teneligliptin 40 mg in type 2 diabetes: A pooled analysis of two phase III clinical studies

Kadowaki T et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0372-x

02-06-2018 | Post-transplant diabetes mellitus | Review | Article

Post-liver transplantation diabetes mellitus: A review of relevance and approach to treatment

Peláez-Jaramillo MJ et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0374-8

01-25-2018 | Heart failure | Review | Article

Effect of glucose-lowering therapies on heart failure

Nat Rev Cardiol 2018; Advance online publication. doi: 10.1038/nrcardio.2017.211

01-08-2018 | Ertugliflozin | Article

Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: The VERTIS SITA randomized study

Miller S et al. Diabetes Ther 2018; 9: 253–268. doi: 10.1007/s13300-017-0358-0

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

01-04-2018 | Medication adherence | Article

A class comparison of medication persistence in people with type 2 diabetes: A retrospective observational study

McGovern A et al. Diabetes Ther 2018; 9: 229–242. doi: 10.1007/s13300-017-0361-5

12-20-2017 | Specific populations | Review | Article

Ethnic differences in efficacy and safety of alogliptin: A systematic review and meta-analysis

Cai Y et al. Diabetes Ther 2018; 9: 177–191. doi: 10.1007/s13300-017-0352-6

11-13-2017 | Vildagliptin | Article

Factors that may account for cardiovascular risk reduction with a dipeptidyl peptidase-4 inhibitor, vildagliptin, in young patients with type 2 diabetes mellitus

Evans M et al. Diabetes Ther 2017; 9: 27–36. doi: 10.1007/s13300-017-0329-5

11-06-2017 | Omarigliptin | Article

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Lee SH et al. BMC Endocr Disord 2017; 17: 70. doi: 10.1186/s12902-017-0219-x

11-02-2017 | Heart failure | Review | Article

Treating disease mechanisms in patients with heart failure and diabetes mellitus

Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

10-23-2017 | Cardiovascular disorders | Review | Article

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Schernthaner G et al. Cardiovasc Diabetol 2017; 16: 137. doi: 10.1186/s12933-017-0622-7

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

10-05-2017 | DPP-4 inhibitors | Review | Article

The role of vildagliptin in the therapy of type 2 diabetic patients with renal dysfunction

Trevisan R. Diabetes Ther 2017; 8: 1215–1226. doi: 10.1007/s13300-017-0302-3

09-08-2017 | Latent autoimmune diabetes of adulthood | Review | Article

Adult-onset autoimmune diabetes: Current knowledge and implications for management

Nat Rev Endocrinol 2017; 13: 674–686. doi: 10.1038/nrendo.2017.99

09-04-2017 | Nephropathy | Review | Article

GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes

Nat Rev Nephrol 2017; 13: 605–628. doi: 10.1038/nrneph.2017.123

07-19-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome trial update in diabetes: New evidence, remaining qestions

Herbst R et al. Curr Diab Rep 2017; 17: 67. doi: 10.1007/s11892-017-0898-8

Next Previous
Image Credits